2. Signaling Pathways
  3. Apoptosis
    Metabolic Enzyme/Protease
  4. Glutathione Peroxidase
  5. GPX4 Isoform
  6. GPX4 Inhibitor

GPX4 Inhibitor

GPX4 Inhibitors (49):

Cat. No. Product Name Effect Purity
  • HY-100218A
    RSL3
    		Inhibitor 99.87%
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
  • HY-100003
    ML-210
    		Inhibitor 99.93%
    ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
  • HY-100002
    ML162
    		Inhibitor 99.52%
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
  • HY-Y0669
    Pipecolic acid
    		Inhibitor 99.92%
    Pipecolic acid is an orally bioavailable, blood-brain barrier-permeable metabolite of lysine with antioxidant, inhibitor, and inducer activity. Pipecolic acid modulates the YAP-GPX4 signaling pathway, reduces retinal vascular tube formation, and mitigates ferroptosis. Pipecolic acid potentiates voltage-sensitive Ca2+ channel currents and induces neuronal apoptosis. Pipecolic acid can be used for the research of diabetic retinopathy.
  • HY-181574
    PDI-IN-5
    		Inhibitor
    PDI-IN-5 (compound 30z) is an allosteric-covalent inhibitor targeting protein disulfide isomerase (PDI) with a 2-chloro-pyrrolopyrimidin-4-one scaffold, with an IC50 of 0.4 μM. PDI-IN-5 exhibits selectivity for ERp57 and GPX4, and inhibits glioblastoma. PDI-IN-5 can be used in glioblastoma-related research.
  • HY-138544
    GPX4-IN-1
    		Inhibitor 99.76%
    GPX4-IN-1 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-1 has the potential for the research of cancer.
  • HY-112005G
    DOPE (GMP)
    		Inhibitor
    DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.
  • HY-138153
    JKE-1674
    		Inhibitor 99.54%
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors.
  • HY-141809
    GPX4-IN-3
    		Inhibitor 99.83%
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.
  • HY-N0070
    Solasonine
    		Inhibitor 99.19%
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research.
  • HY-155663
    GPX4-IN-5
    		Inhibitor 99.73%
    GPX4-IN-5 is a covalent inhibitor of GPX4 (IC50: 0.12 μM). GPX4-IN-5 can induce ferroptosis and has anti-tumor effects. GPX4-IN-5 can be used in the study of triple-negative breast cancer (TNBC).
  • HY-Y0669S
    Pipecolic acid-d9
    		Inhibitor 99.9%
    Pipecolic acid-d9 is the deuterium labeled Pipecolic acid. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
  • HY-149923
    GPX4-IN-4
    		Inhibitor 98.94%
    GPX4-IN-4 (Compound 24) is a potent GPX4 inhibitor. GPX4-IN-4 can be used for the research of cancer.
  • HY-34765
    Propiolamide
    		Inhibitor 99.94%
    Propiolamide is a monooxygenase (MMO) system activator and glutathione peroxidase 4 (GPX4) inhibitor. Propiolamide induces ROS production through interaction with the MMO system. Propiolamide promotes the accumulation of intracellular cytotoxic lipid peroxides and induces ferroptosis. Propiolamide induces programmed cell death via the apoptosis pathway. Propiolamide can be used in cancer research.
  • HY-167888
    NPD4928
    		Inhibitor 99.48%
    NPD4928, a GPX4 inhibitor, enhances RSL3 (HY-100218A)-dependent ferroptosis. NPD4928 binds to ferroptosis suppressor protein 1 (FSP1) and inhibits its enzymatic activity.
  • HY-155664
    GPX4-IN-6
    		Inhibitor 99.65%
    GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
  • HY-139001
    JKE-1716
    		Inhibitor 98.04%
    JKE-1716 is a potent and selective nitrolic acid-containing GPX4 inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent GPX4 inhibition.
  • HY-157762
    GPX4-IN-9
    		Inhibitor 99.18%
    GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research.
  • HY-176557
    NCI677397
    		Inhibitor
    NCI677397 is a USP24 inhibitor. NCI677397 increases lipid ROS, activates cholesterol and fatty acid biosynthesis, degrades ABC transporters, GPX4 and DHFR through the autophagy pathway, decreases the level of P-gp and ultimately leads to ferroptosis in drug-resistant cancer cells. NCI677397 can be used for the study of lung caner and brain cancer.
  • HY-175615
    RSL3-NH2
    		Inhibitor
    RSL3-NH2 is a GPX4 inhibitor and ferroptosis inducer. RSL3-NH2 triggers the iron-dependent cell death pathway associated with lipid peroxidation by inhibiting GPX4 activity. RSL3-NH2 exhibits significant cytotoxicity against colorectal cancer cells and effectively induces their ferroptosis. RSL3-NH2 can serve as a ADC payload for synthesizing antibody-drug conjugates (ADC) and be used in colorectal cancer-related research.